What is Leerink Partnrs’ Estimate for ORKA FY2028 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Analysts at Leerink Partnrs issued their FY2028 EPS estimates for shares of Oruka Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings per share of ($2.92) for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($1.69) per share.

A number of other brokerages have also recently commented on ORKA. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Leerink Partners started coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 target price for the company. Stifel Nicolaus began coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price target on the stock. Wedbush initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, TD Cowen began coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating on the stock. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Stock Performance

ORKA opened at $24.04 on Friday. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88. The business’s fifty day moving average price is $26.78. The firm has a market capitalization of $29.09 million, a PE ratio of -3.84 and a beta of 0.87.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at $1,037,000. Wellington Management Group LLP bought a new position in shares of Oruka Therapeutics in the third quarter valued at $2,013,000. Janus Henderson Group PLC acquired a new position in shares of Oruka Therapeutics during the third quarter valued at about $5,840,000. Redmile Group LLC acquired a new position in shares of Oruka Therapeutics during the third quarter valued at about $10,091,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in shares of Oruka Therapeutics during the third quarter worth about $11,699,000. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.